04.03.2018
- MedImmune, the biologics R&D arm of Anglo-Swedish drugmaker AstraZeneca, is spinning out six molecules from its early-stage inflammation and autoimmunity programs into new...
02.12.2016
- AstraZeneca’s biologics R&D arm MedImmune and US life sciences group Abpro have spun out a new company – AbMed – to advance the development of a preclinical, novel bispecific...
10.02.2016
- The combination of two cancer drugs from UK-Swedish drugs maker AstraZeneca and its biologics research and development arm MedImmune could be a potential breakthrough in treating a...
14.09.2015
- As a first step toward doubling its manufacturing and production capacity for biologics in the US, AstraZeneca has acquired a high-tech biologics bulk manufacturing facility in...
26.06.2015
- ADC Therapeutics announced the appointment of Dr Chris Martin as its CEO. Dr Martin was co-founder of Spirogen and its CEO leading up to the sale of Spirogen to MedImmune, the...
20.05.2013
- AstraZeneca is closing in on a site for its new $500 million home in Cambridge, with a biomedical park just south of the English city the most likely site, property industry...
03.04.2013
- AstraZeneca boosted its early-stage pipeline of experimental heart drugs on Wednesday by buying privately held U.S. biotechnology company AlphaCore Pharma, which is developing a...
15.01.2013
- AstraZeneca's new chief executive stamped his authority on the struggling drugmaker on Tuesday by removing the heads of research and commercial operations. Pascal Soriot, who took...
